[{"id":"cec10506-6390-45ed-9785-1b2e4ff57e38","acronym":"QLMA-NSCLC-IIT-001","url":"https://clinicaltrials.gov/study/NCT06697990","created_at":"2025-02-26T13:42:05.793Z","updated_at":"2025-02-26T13:42:05.793Z","phase":"Phase 2","brief_title":"Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients","source_id_and_acronym":"NCT06697990 - QLMA-NSCLC-IIT-001","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" CD8 • IFNG • IL6 • TNFA • CD4 • VCAM1 • CRP","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL6 • TNFA • CD4 • VCAM1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-11-20"},{"id":"b1ea2168-c575-4d9f-b230-d040034ef8b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04632758","created_at":"2021-01-19T20:36:49.478Z","updated_at":"2024-07-02T16:35:28.115Z","phase":"Phase 3","brief_title":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT04632758","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Qi Xinke (iruplinalkib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-24"},{"id":"b4a235ca-d5ba-4354-85dc-09fefd632f48","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991895","created_at":"2023-08-15T19:10:05.345Z","updated_at":"2024-07-02T16:35:40.003Z","phase":"","brief_title":"Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05991895","lead_sponsor":"Jinming Yu","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 07/24/2023","start_date":" 07/24/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-08-15"},{"id":"6ed7310f-1b32-4649-afa5-8be315afc925","acronym":"","url":"https://clinicaltrials.gov/study/NCT05765877","created_at":"2023-03-13T15:02:23.189Z","updated_at":"2024-07-02T16:35:53.504Z","phase":"Phase 2","brief_title":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05765877","lead_sponsor":"Pingping Song","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-03-13"},{"id":"20e2f375-969b-462d-918f-19a2d961752d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05351320","created_at":"2022-04-28T16:56:59.658Z","updated_at":"2024-07-02T16:36:11.314Z","phase":"Phase 2","brief_title":"WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC","source_id_and_acronym":"NCT05351320","lead_sponsor":"Jinming Yu","biomarkers":" ALK • ROS1","pipe":"","alterations":" ","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/30/2022","start_date":" 04/30/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2022-04-28"},{"id":"8ebf976b-238e-421b-8483-823d7b4e244d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641754","created_at":"2021-01-19T20:38:48.770Z","updated_at":"2024-07-02T16:36:38.236Z","phase":"Phase 2","brief_title":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04641754","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Qi Xinke (iruplinalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 03/07/2019","start_date":" 03/07/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2020-11-24"},{"id":"c6c1a81b-7416-4de1-ac49-3346031ecb17","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389815","created_at":"2021-01-18T16:43:48.745Z","updated_at":"2024-07-02T16:37:15.118Z","phase":"Phase 1/2","brief_title":"A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients","source_id_and_acronym":"NCT03389815","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Unknown status","enrollment":" Enrollment 48","initiation":"Initiation: 09/14/2017","start_date":" 09/14/2017","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2018-01-04"}]